about
S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytesThe W105G and W99G sorcin mutants demonstrate the role of the D helix in the Ca(2+)-dependent interaction with annexin VII and the cardiac ryanodine receptorA Pre-clinical Animal Model of Trypanosoma brucei Infection Demonstrating Cardiac DysfunctionThe effect of K201 on isolated working rabbit heart mechanical function during pharmacologically induced Ca2+ overload.Two candidates at the heart of dysfunction: The ryanodine receptor and calcium/calmodulin protein kinase II as potential targets for therapeutic intervention-An in vivo perspective.Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling.Gene Therapy With Angiotensin-(1-9) Preserves Left Ventricular Systolic Function After Myocardial InfarctionK201 (JTV-519) alters the spatiotemporal properties of diastolic Ca(2+) release and the associated diastolic contraction during β-adrenergic stimulation in rat ventricular cardiomyocytes.Trypanosoma brucei cathepsin-L increases arrhythmogenic sarcoplasmic reticulum-mediated calcium release in rat cardiomyocytes.Advancing our understanding of the pathophysiology of cardiac disease using in vivo assessment of heart structure and function in rodent models.Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes.Runx1 Deficiency Protects Against Adverse Cardiac Remodeling After Myocardial Infarction.Overexpression of FK-506 binding protein 12.0 modulates excitation contraction coupling in adult rabbit ventricular cardiomyocytesK201 modulates excitation-contraction coupling and spontaneous Ca2+ release in normal adult rabbit ventricular cardiomyocytesIsolated rabbit working heart function during progressive inhibition of myocardial SERCA activityRUNX1: an emerging therapeutic target for cardiovascular diseaseWhat matters in Cardiovascular Research? Scientific discovery driving clinical delivery
P50
Q28258841-06F9834D-6AAD-4736-ACDF-8519BFB9FAC8Q28512701-B95E0E15-0E74-4EFE-AE2E-685E56EEC58DQ28547618-B6696B7A-BB1E-4DB5-8EA2-A2F13735B0DCQ35940357-3DB31324-1D62-46FC-B782-02C1EC00350FQ37854147-53200684-3D63-4E39-A79E-6228E1AA3242Q38193206-AEF2F94B-DBE4-4761-9D04-04DEC22D21E5Q39097850-07730DBA-2720-4331-A809-BA64BE79F0E0Q39542247-8860E35A-E901-46E3-9FA4-947910113388Q41882342-A04E6C72-86B4-483D-A572-C46C2B4B3BD0Q43871964-7DBF4FFD-B09A-4055-9678-02C2F7DEB057Q46435116-24AF74A6-E56B-465F-9E84-796BE20930BBQ47613009-D0A6C4B1-B9A7-4870-93AB-1ADEFC2FEB56Q64376978-AF635CEC-A1D1-42B4-85C6-353F0071362AQ80650258-6EA71612-A4BE-4D88-9298-39B69B2C4C95Q84068254-8841E35D-6961-434A-9210-98BAADCE87E5Q90185168-392BB1F3-AF6C-419E-AD28-7397AE8B9124Q90980943-4C71D7DA-4451-4E52-AAFD-3A4C9FAFAA14
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christopher M Loughrey
@nl
Christopher M Loughrey
@sl
Christopher M. Loughrey
@en
Christopher M. Loughrey
@es
type
label
Christopher M Loughrey
@nl
Christopher M Loughrey
@sl
Christopher M. Loughrey
@en
Christopher M. Loughrey
@es
prefLabel
Christopher M Loughrey
@nl
Christopher M Loughrey
@sl
Christopher M. Loughrey
@en
Christopher M. Loughrey
@es
P106
P1153
6701465928
P21
P31
P496
0000-0003-1297-9159